BeiGene Corporate Presentation

February 27, 2023

Disclosures

Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans; recent clinical data for BeiGene's product candidates and approvals of its medicines; the conduct of late-stage clinical trials and expected data readouts; additional planned commercial product launches; and the advancement of and anticipated clinical development, regulatory milestones and commercialization of BeiGene's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene's clinical development, commercial, regulatory and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Some of the clinical data in this presentation relating to BeiGene's investigational drug candidates is from pre-clinical studies or early phase, single-arm clinical trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between BeiGene's investigational drug candidates and other products unless specified in the trial protocol. BeiGene is still conducting pre-clinical studies and clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene's investigational drug candidates may change.

This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above.

New slide for IR deck. Was used

BeiGene

Founded
2010

@BeiGeneGlobal BeiGene

Numbers as of December 2022

~40 offices, **9,000+** colleagues on **5** continents

$1.3B in annual product revenue
+98% product revenue growth
$4.5B cash balance*

3,500+ global commercial team
16 approved products

950+ oncology research team

2,700 global clinical development & medical affairs team

In-house manufacturing plus U.S. expansion under construction

60+ pre-clinical programs, the majority with first-in-class potential

~50 assets in clinical and commercial stages

~20 industry collaborations

Truly Unique with Hard to Replicate Competitive Advantages

One of the world's largest oncology research teams (950+)
Validated by clinical results, global approvals, and major global pharma collaborations

Cost and time advantaged clinical development
Due to unique approach – more globally inclusive, superior technology, pre-dominantly internal (CRO-free)

Cornerstone commercial medicines that are key to combinations for future, complemented by a strong, deep, and innovative clinical portfolio

Truly global commercial footprint (3,500+)
Driving broader access to medicines, with expected rapidly growing revenue and near-term potential milestones

Financial strength, disciplined investments, and operational effectiveness
Contributing to long-term value creation

TRANSLATING SCIENCE TO IMPROVE ACCESS AND AFFORDABILITY BY CHALLENGING THE STATUS QUO

Trials Span

45+

Countries & Regions

20K+

People Enrolled in

110+

Clinical Trials



Differentiated Biological Hypothesis and First-in-Class Programs Based on Deep Oncology Insights from the Bench

- **BTK -** Higher exposure, better selectivity, targeted inhibition
- **PD-1 -** Fc function silenced
- **TIGIT -** Intact Fc function, first wave
- **BCL2 -** Higher potency, increased selectivity, and shorter half life
- **BTK Degrader -** Potentially first-in-class, eliminates both kinase and non-kinase function of BTK, should inhibit BTKi resistant strains
- **OX-40 -** Only OX-40 Ab not interfering with OX-40 ligand binding
- **HPK-1 -** Potentially first-in-class intracellular checkpoint inhibitor
- **CEA-41BB -** Potentially first-in-class immune activator, converting immune cold tumor to hot

Differentiated biological hypothesis

Potential first-in-class, or first wave

Productive Research and Path to Global Oncology Leadership



Prolific First Decade

2013 - 2015

BRAF
PARP*
BTK*
PD-1*

2016 - 2020

TIM-3
TIGIT
BCL-2
OX40
PI3Kd

Entering a New Era of Discovery

2021-2023

HPK-1
TYK2
SMAC mimetic
BTK-Targeted CDAC
CEA x 4-1BB bispecific

4+ NMEs in 2023

SM and mAb: 20+ New programs
ADC: 10+ TAAs
Pro-Cytokine

2024+

10 New Molecules in the Clinic Expected Annually

CDAC: Total 7+ programs
BsAb/TsAb: 10 new programs
mRNA Therapy

Cell therapy: CAR-NK and more

*Approved 2019-2021

SM, Small Molecule; mAb, Monoclonal Antibody; ADC, Antibody Drug Conjugate; TAA, Tumor Associated Antigen; CDAC, Chimeric Degradation Activating Compound (targeted protein degradation); BsAb, Bispecific Antibody; TsAb, Trispecific Antibody; CAR-NK, Chimeric Antigen Receptor-Natural Killer Cell, NME, New Molecular Entity

BRUKINSA Superiority to Ibrutinib Core to Hematology Franchise*

Best-in-Class Hypothesis

- Complete and sustained target inhibition in disease originating tissues
- Maintains therapeutic concentrations over 24 hours
- Equally or more selective than any approved BTKi

Broad Global Clinical Program

4,800+ Subjects

- **35** trials across **29** markets
- Two head-to-head studies versus ibrutinib – 800+ subjects
- Comprehensive label vs. next generation BTKi (approved in CLL, MCL, WM, MZL)

Demonstrating Clinical Advantages

- First and only BTKi to demonstrate superior efficacy versus ibrutinib – ORR and PFS
- Favorable safety versus ibrutinib with improved cardiac profile - Afib, and 0% vs 1.9% sudden cardiac death in ALPINE
- Dosing flexibility – QD / BID

*Superior to ibrutinib in ORR & PFS for R/R CLL in ALPINE trial.

BeiGene

ALPINE: BRUKINSA PFS & ORR Superiority to Ibrutinib in R/R CLL/SLL 2022 ASH Late Breaker & Concurrent NEJM Manuscript

BRUKINSA PFS by IRC Significantly Superior to Ibrutinib



No. at Risk															
Zanubrutinib	327	315	304	301	294	280	263	226	172	161	125	113	14	2	0
Ibrutinib	325	305	293	277	260	246	228	191	133	123	98	87	9	2	2	0

BRUKINSA Improved PFS in Patients with del(17p)/*TP53*^{mut}



No. at Risk															
Zanubrutinib	75	71	68	67	64	62	58	49	35	30	21	19	3	0
Ibrutinib	75	70	66	60	55	49	45	34	18	16	10	10	2	0

Data cutoff: 8 Aug 2022. Brown J et al. NEJM 2022. DOI: 10.1056/NEJMoa2211582

Potential for Substantial BRUKINSA Growth

BRUKINSA Global Product Revenues



$20.4B BTKi Global Market by 2026*



*Data for 2023-2026 from Deutsche Bank Report 2022

Tislelizumab Well Positioned for Global Success

1 Mechanistically differentiated, Fc-γ receptor sparing, and multiple combinations under study

2 Realizing Impact from favorable labels and NRDL coverage in China

- Achieved #1 value market share in China despite late to market; future filings in ROW

3 Broad clinical program, including:

- **21** registration-enabling clinical trials
- **11,800+** subjects enrolled in clinical trials in **30+** countries and regions, with **4,000+** from outside of China

4 Commitment to quality, global manufacturing

- Built state-of-the-art facility in Guangzhou, building toward 200,000L of biologics capacity
- Collaboration with one of the world's leading biologics manufacturers

Boehringer Ingelheim | **25 global biologics manufacturing approvals**

5 Future global approvals in more indications, and combinations

- 10 approved indications in China: R/R cHL, R/R UC, 1L Sq, 1L non-Sq NSCLC, 2L/3L HCC and 2L/3L NSCLC, 2L/3L MSI-H or dMMR solid tumors, 2L ESCC, 1L NPC, 1L G/GEJ
- 1 filing in the U.S.: 2L ESCC*, 2 filings in Europe: NSCLC & ESCC, filings in Australia and UK in NSCLC & 2L ESCC, and 2 in China in 1L ESCC & 1L HCC.
- 11 other pivotal or potentially registration-enabling studies ongoing; compelling breadth of combinations e.g., ociperlimab, sitravatinib, zanidatamab, etc.
- IO combination trials underway to drive success

Collaboration with Novartis

- Acceleration of global development in Novartis territory: North America, Europe, and Japan
- Further explore combination opportunities with Novartis pipeline
- Eligible for up to $1.5 billion collaboration revenue from Novartis

*Subject to completion of regulatory inspections which have been delayed due to COVID-19 travel restrictions. cHL = classical Hodgkin's lymphoma; CR = complete response; dMMR = Deficient Mismatch Repair; ESCC = Esophageal Squamous-Cell Carcinoma; HCC = hepatocellular carcinoma; MSI-H = microsatellite instability-high; NRDL = China National Reimbursement Drug List; non-Sq: non-squamous; NPC = Nasopharyngeal carcinoma; NSCLC = non small cell lung cancer; R/R = relapsed/refractory; Sq = squamous; UC = urothelial carcinoma

BeiGene's Internal Discovery

For our full pipeline, including single-country trials, please visit beigene.com/our-science-and-medicines/pipeline
*Enrolling in the U.S.; **First-in-human trial, healthy subjects; †This combination is being studied in the third cohort of NCT03336333, ^SMAC = second mitochondrial-derived activator of caspase

Asset	Program	Phase 1	Phase 2	Phase 3
Zanubrutinib (BTK inhibitor)	monotherapy			R/R CLL/SLL
	+ rituximab			TN MCL and R/R MZL
	+/- venetoclax (Bcl-2 inhibitor)†			TN CLL/SLL
	+ obinutuzumab (anti-CD20)		R/R FL	
Tislelizumab (anti-PD-1)	monotherapy			2L advanced ESCC, 1L HCC, 2L/3L NSCLC
	monotherapy		Previously treated HCC, R/R cHL	
	+ chemotherapy			1L advanced ESCC, 1L GC/GEJC, 1L NPC
	+ zanidatamab (anti-HER2 bi-specfic antibody) + chemotherapy			1L GEA
	+ sitravatinib (RTK inhibitor)	Solid tumors		2L NSCLC
	+ fruquintinib (VEGFR)*		Solid tumors	
Ociperlimab (anti-TIGIT)	+ tislelizumab			1L PD-L1 high NSCLC
			2L PD-L1+ ESCC, 2/3 L Cervical cancer	
		Solid tumors		
	+ tislelizumab + chemotherapy		1L NSCLC	
	+ tislelizumab + concurrent chemoradiotherapy			LA NSCLC (PD-L1+)
			1L LS-SCLC	
BGB-11417 (Bcl-2 inhibitor)	monotherapy		R/R MCL, R/R CLL/SLL	
	+/- zanubrutinib	Mature B-cell malignancies		
	+ azacitidine +/- posaconazole		Myeloid malignancies	
	+ dexamethasone +/- carfilzomib		R/R multiple myeloma with t(11;14)	
BGB-16673 (BTK-targeted CDAC)	monotherapy	B-cell malignancies		
BGB-A445 (anti-OX40)	+ tislelizumab	Solid tumors		
BGB-15025 (HPK1 inhibitor)	+ tislelizumab	Solid tumors		
Surzebiclimab (BGB-A425, anti-TIM-3)	+ tislelizumab +/- LBL-007 (LAG-3 mAb)		Solid tumors	
BGB-10188 (PI3K inhibitor)	+ tislelizumab	Solid tumors		
	+/- zanubrutinib	B-cell lymphoid malignancies		
	+/- tislelizumab	B-cell malignancies		
Pamiparib (PARP 1/2 inhibitor)	monotherapy		1L maintenance platinum-sensitive GC	
	+ temozolomide	Solid tumors		
BGB-3245 (BRAF inhibitor)	monotherapy	Solid tumors with *BRAF* mutations		
Lifirafenib (RAF inhibitor)	+ mirdametinib (MEK inhibitor)	Solid tumors		
BGB-23339 (TYK2 inhibitor)**	monotherapy	Inflammation and immunology		
BGB-24714 (SMAC mimetic)^	+/- chemotherapy	Solid tumors		
BGB-B167 (CEA x 4-1BB bispecific)	+/- tislelizumab	Solid tumors		

Pipeline from Collaborations

Partner	Molecule / Asset	Indications	Phase	Commercial Rights
AMGEN	Sotorasib	Solid tumors, CRC, NSCLC	Phase 3	China
	tarlatamab ^^	SCLC	Phase 2	China
	acapatamab ^^	Prostate cancer, NSCLC	Phase 1	China
	AMG 176	Hematologic malignancies	Phase 1	China
	AMG 427 ^^	AML	Phase 1	China
	AMG 509	Prostate cancer	Phase 1	China
	AMG 199 ^^	GC/GEJC	Phase 1	China
	AMG 650	Solid tumors	Phase 1	China
	AMG 256	Solid tumors	Phase 1	China
MIRATI THERAPEUTICS	Sitravatinib † + Tislelizumab	NSCLC	Phase 3	Asia, Australia, New Zealand
	Sitravatinib † + Tislelizumab	HCC, GC/GEJC	Phase 2	Asia, Australia, New Zealand
	Sitravatinib † + Tislelizumab	Solid tumors	Phase 1	Asia, Australia, New Zealand
zymeworks	Zanidatamab + chemo + Tislelizumab	GEA	Phase 3	Asia, Australia, New Zealand
	Zanidatamab (monotherapy)	BTC	Phase 2	Asia, Australia, New Zealand
	Zanidatamab	BC, GC, GEA	Phase 2	Asia, Australia, New Zealand
	ZW49	HER2 expressing cancers	Phase 1	Asia, Australia, New Zealand
SpringWorks THERAPEUTICS	BGB-3245[1]	Solid tumors	Phase 1	Asia
Seagen	SEA-CD70	MDS, AML	Phase 1	Asia, Australia, New Zealand
leaptherapeutics	DKN-01 + Tislelizumab + Chemo	GC/GEJC	Phase 2	Asia, Australia, New Zealand
Leads Biolabs	LBL-007 + Tislelizumab	Advanced solid tumors	Phase 2	Ex-China
assemblybio	ABI-H3733	Chronic hepatitis B virus	Phase 1	China

^ BiTE® molecule, ^^Half-life extended BiTE † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non Sq NSCLC, †† ZW25,
* Assembly is conducting Phase 2 triple combination studies with VBR and a Phase 1 study of ABI-H3733, 1 By MapKure, a JV with SpringWorks.

Growing Commercial Portfolio: 16 Approved Assets

Product	Lead Indications	Mechanism of Action	Regulatory Status	Our Commercial Rights	Partner
Brukinsa® zanubrutinib	U.S.: CLL,R/R MCL[1], WM & R/R MZL[1]; China: R/R MCL[2], R/R CLL/SLL[2] & R/R WM[2]; EU[3]: CLL, WM & MZL	BTK inhibitor	Approved in the U.S., China, EU and other markets	Global	BeiGene
Tislelizumab	China:1L Squamous and Non-Squamous NSCLC, 2/3 L NSCLC, R/R classical Hodgkin's lymphoma[2], 2/3 L HCC[2], R/R PD-L1+ UC[2], 2L ESCC, MSI-H or dMMR solid tumors[2], 1L NPC, 1L G/GEJ	Anti-PD-1 antibody	Approved in China BLA Accepted in U.S.[4] MAA accepted in EU[5]	Outside North America, Japan, UK, AU, EU and six other European countries	NOVARTIS
百汇泽 pamiparib	3L BRCA-mutated ovarian cancer[2]	PARP Inhibitor	Approved in China	Global	BeiGene
XGEVA® (denosumab)	Giant cell tumor of bone[2], Skeletal Related Events (SREs)[2]	Anti-RANK ligand antibody	Approved in China	Mainland China	AMGEN
BLINCYTO® (blinatumomab)	R/R Acute lymphocytic leukemia[2]	Anti-CD19 x anti-CD3 bispecific T-cell engager (BiTE)	Approved in China	Mainland China	AMGEN
Kyprolis® (carfilzomib)	R/R Multiple myeloma[2]	Proteasome inhibitor	Approved in China	Mainland China	AMGEN
Revlimid® (lenalidomide)	R/R adult multiple myeloma, newly diagnosed multiple myeloma, previously treated follicular lymphoma	Anti-angiogenesis, immuno-modulation	Approved in China	Mainland China	Bristol Myers Squibb
Vidaza® azacitidine	Myelodysplastic syndromes, acute myeloid leukemia, chronic myelomonocytic leukemia	DNA hypomethylation	Approved in China	Mainland China	Bristol Myers Squibb
sylvant® siltuximab	Idiopathic multicentric Castleman disease	IL-6 antagonist	Approved in China	Greater China	EUSAPharma
Qarziba® dinutuximab beta	High-risk neuroblastoma[2]	Anti-GD2 antibody	Approved in China	Mainland China	EUSAPharma

1. Approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 2. Conditionally approved. The full approval of any particular indication will depend on the results of required post-marketing study(ies) in China. 3. The approval is applicable to all 27 EU member states, plus Iceland, Lichtenstein and Norway. 4. For patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy, 5. For patients with advanced or metastatic ESCC after prior systemic chemotherapy and for patients with NSCLC including: locally advanced or metastatic NSCLC after prior chemo, in combination with chemo for 1L advanced or metastatic squamous NSCLC, and in combination with chemo for 1L locally advanced or metastatic non-squamous NSCLC with no EGFR or ALK positive mutations. BLINCYTO, KYPROLIS, and XGEVA are registered trademarks of Amgen.

Growing Commercial Portfolio
WITH 16 APPROVED ASSETS

PRODUCT	LEAD INDICATIONS	MECHANISM OF ACTION	REGULATORY STATUS	OUR COMMERCIAL RIGHTS	PARTNER
POBEVCY® (Avastin biosimilar)	Colorectal, lung, glioblastoma, ovarian, and cervical cancers[8]	Anti-VEGF antibody	Approved in China	Greater China	百奥泰 BIO-THERA
TAFINLAR® (dabrafenib)	Melanoma[5]	BRAF inhibitor	Approved in China	China Broad Markets[7]	NOVARTIS
MEKINIST® (trametinib)	Melanoma[5]	MEK inhibitor	Approved in China	China Broad Markets[7]	NOVARTIS
VOTRIENT® (pazopanib)	Advance renal cell carcinoma	VEGFR inhibitor	Approved in China	China Broad Markets[7]	NOVARTIS
AFINITOR® (everolimus)	Advance renal cell carcinoma[6]	mTOR inhibitor	Approved in China	China Broad Markets[7]	NOVARTIS
ZYKADIA® (ceritinib)	ALK + NSCLC	ALK inhibitor	Approved in China	China Broad Markets[7]	NOVARTIS

5. TAFINLAR and MEKINIST are being investigated in combination by Novartis for NSCLC indications. 6. Following progression on or after vascular endothelial growth factor (VEGF)-targeted therapy. 7. Rights to promote and market in China's broad markets pursuant to a Market Development Agreement with an affiliate of Novartis Pharma AG dated December 19, 2021. 8. Please see full labeling for indication details.
Abbreviations: ALK = anaplastic lymphoma kinase; BLA = Biologics License Application; BRAF = B-rapidly accelerated fibrosarcoma; CLL = chronic lymphocytic leukemia; HCC = hepatocellular carcinoma; MCL = mantle cell lymphoma; MEK = mitogen-activated protein kinase (MAPK) / Extracellular-signal regulated kinase (ERK); MSI = microsatellite instability-high; mTOR = Mammalian target of rapamycin; MZL = marginal zone lymphoma; NPC = nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed / refractory; SLL = small lymphocytic lymphoma; UC = urothelial carcinoma; VEGFR = vascular endothelial growth factor receptor; WM = Waldenström's macroglobulinemia

Growing Commercial Revenue Stream





We Work Collaboratively with Our Partners, Large and Small, Regionally and Globally, to Provide Innovative Medicines to Patients Faster

Multinational Corporations

Bristol Myers Squibb™
Vidaza, Revlimid, Abraxane,

AMGEN®
BLINCYTO, Kyprolis, XGEVA

NOVARTIS
Taflinar, Mekinist, Votrient, Affinitor, Zykadia
Tislelizumab, Ociperlimab

Small and Mid-sized Companies

assemblybio
Vebicorvir

百奥泰 BIO-THERA

BITT

EUSAPharma
Acquired by Recordati (2021)
Qarziba, Sylvant

HUTCHMED

leaptherapeutics
anti-DKK1

Leads Biolabs
anti-LAG-3

MEI Pharma

MIRATI THERAPEUTICS
Sitravatinib

Mapkure
JV with SpringWorks

SpringWorks THERAPEUTICS

Seagen®
anti-CD70nt

zymeworks
Zanidatamab,
ZW49

Access to Innovation

SHORELINE biosciences
Entry into cell therapy with iPSC-derived NK CAR

STRAND THERAPEUTICS
Entry into mRNA therapeutics

INNOVENT 深信生物
Entry into LNP therapeutics

Clinical Supply Agreements for Combination

Abbisko 和誉

Asieris

德琪医药 ANTENGENE

微芯生物 CHIPSCREEN

Gopherwood Biotech

HARBOUR BIOMED

IMMiX

IMMUNE-ONC therapeutics

Prelude THERAPEUTICS

Phanes Therapeutics

PURETECH

Simcere

TiUM

BeiGene

Financial Summary

Selected Financials	Three Months Ended		Twelve Months Ended	
Amounts in thousands of U.S. dollars	Dec. 31, 2022 (unaudited)	Dec. 31, 2021[1] (unaudited)	Dec. 31, 2022 (audited)	Dec. 31, 2021[1]
Total Revenue	$ 380,095	$ 213,979	$ 1,415,921	$1,176,283
Product revenue, net	339,022	196,785	1,254,612	633,987
Collaboration revenue	41,073	17,194	161,309	542,296
Total Expenses*	(848,717)	(785,718)	(3,205,586)	(2,615,018)
Cost of sales – products	(73,522)	(48,545)	(286,475)	(164,906)
Research and development	(446,023)	(430,485)	(1,640,508)	(1,459,239)
Selling, general and administrative	(328,984)	(306,501)	(1,277,852)	(990,123)
Loss from operations	(468,622)	(571,739)	(1,789,665)	(1,438,735)
Interest income (expense), net	18,219	(4,482)	52,480	(15,757)
Other income (expense), net	19,438	(10,583)	(223,852)	15,904
Net loss attributable to BeiGene, Ltd.^	$ (445,335)	$ (590,678)	$ (2,003,815)	$ (1,457,816)
Net loss per share basic and diluted	(0.33)	(0.48)	(1.49)	(1.21)
Net loss per American Depositary Share (ADS)†	($4.29)	($6.22)	(19.43)	(15.71)
Cash, cash equivalents, restricted cash, and short-term investments	$ 4,540,288	$ 6,624,849		
Cash used in operations	$ (318,191)	$ (507,839)		

1 see Notes 2 and 3 in the 10-K on the revision of prior period financial statements for details on the immaterial error related to the valuation of net deferred tax assets in 1Q and 2Q 2022 and FY 2021
*Contains $188 and $187 of amortization expense, which is not included in SG&A, R&D or COGS, for the three months ended Dec. 31, 2022 and 2021, respectively. Amortization expenses were $751 and $750 for the year ended Dec. 31, 2022 and 2021, respectively. ^Net loss attributable includes $14,370 and $3,874 of tax expense for the three months ended Dec. 31, 2022 and 2021 and $42,778M and $19,228M for the year ended Dec. 31, 2022 and 2021.† Net loss for 2022 was negatively impacted by other non-operating expenses of $223.9 million, primarily related to foreign exchange losses resulting from the strengthening of the U.S. dollar and the revaluation impact of foreign currencies held in U.S. functional currency subsidiaries.

BeiGene

Our Commitment to ESG

Our global strategy is focused on five areas supported by ten strategic priorities.

We will share our progress against our 2022 targets and announce new goals in our 2022 ESG Report to be published in April.

KEY GLOBAL 2022 ESG GOALS

Change Is the Cure focuses on five key areas most material to our business

Bringing affordable cutting-edge medicines to more people around the world

- Define pricing principles and affordability strategy

Fostering a dynamic, rewarding and inclusive workplace

- Develop a three-year global strategy to improve DEI across the company
- Improve colleague engagement by 3 percent globally versus 2020 engagement scores
- Roll out global initiative to address work-life balance

Reducing our environmental impacts

- Expand GHG inventory to include scope 3 emissions
- Conduct climate risk assessment
- Set a global climate strategy

Advocating for patients and giving back to local communities

- Develop a three-year patient engagement and advocacy strategy
- Launch colleague engagement and volunteer events in the various countries we operate

Promoting good governance in our operations and supply chain

- Become a signatory of the U.N. Global Compact
- Introduce procurement academy, including training on responsible sourcing
- Implement a third-party risk management program

DEI = diversity, equity and inclusion; GHG = greenhouse gas

2023 Milestones and Catalysts

		1H 2023	2H 2023
BRUKINSA® (zanubrutinib, BTK Inhibitor)	Approval	✓ FDA decision on sNDA for treatment of CLL/SLL (PDUFA)	
	Approval	Approvals in China for TN CLL/SLL and WM	
	Regulatory submission	Regulatory submissions in US and EU for PFS superiority vs. ibrutinib in R/R CLL - ALPINE	
	Approval	Approvals in Canada and Australia for CLL/SLL	
Tislelizumab (anti-PD-1 Ab)	Approval	Regulatory decision in US for 2L ESCC, in collaboration with Novartis*	
	Approval	Approval in China for ✓ 1L GC & for 1L ESCC	Approvals in China in 1L HCC
	Approval		Approvals in Australia for NSCLC & 2L ESCC
	Approval	Approvals in EU for NSCLC & 2L ESCC, in collaboration with Novartis	
	Regulatory submission	Submissions in US for 1L gastric cancer & 1L ESCC / in EU for 1L gastric cancer, 1L ESCC & 1L NPC, in collaboration with Novartis	
	Data	Final analyses for 1L ES-SCLC & gastric cancer	
	Regulatory submission	BLA submission in Japan for 1L/2L ESCC	

*Pending regulatory inspections

2023 Milestones and Catalysts (cont'd)

		1H 2023	2H 2023
BGB-11417 (BCL-2)	Study progress		Initiate global pivotal trial in 1L CLL in combo with BRUKINSA
	Data readout		Data readouts from ongoing studies
Ociperlimab (anti-TIGIT Ab)	Data readout	Ph2 data available in multiple indications to inform subsequent development	
	Study progress	Complete enrollment in Ph3 AdvanTIG 302 in 1L NSCLC	
BGB-16673 (BTK Degrader)	Data readout	Initial data readout from Phase I study	
BGB-A445 (anti-OX40)	Data readout	Initial data readout for Phase 1 study in solid tumors	
BGB-15025 (HPK1 inhibitor)	Data readout	Initiate dose expansion in combination with tislelizumab in solid tumors	
LBL-007 (anti-LAG-3)	Study progress	Initiate patient dosing + tislelizumab in umbrella studies	
Additional Early Programs	Study progress	Initiate 15 novel IO combos across 6 trials with tislelizumab including LAG3, OX40, TIM3, TIGIT, and HPK1, targeting multiple new tumor types including HNSCC, CRC, UBC, RCC, melanoma	

Key Takeaways

1. BeiGene's transformational next-generation model is leveraging unique global opportunities created by worldwide industry changes.

2. We are building a global ecosystem of innovation, cost, and speed competitive advantages that are designed to outperform key success indicators heralded by our evolving industry.

3. We fight for life against cancer —internally and with partners— in the unrelenting pursuit for exceptional science, quality, and impact by cost-effectively driving global operational excellence.

4. We aspire to deliver improved medicines to more patients around the world, more affordably.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. GAAP)

(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2022	2021 [1]	2022	2021 [1]
	(unaudited)		(audited)	
Revenue:				
Product revenue, net	$ 339,022	$ 196,785	$ 1,254,612	$ 633,987
Collaboration revenue	41,073	17,194	161,309	542,296
Total revenues	380,095	213,979	1,415,921	1,176,283
Expenses:				
Cost of sales - products	73,522	48,545	286,475	164,906
Research and development	446,023	430,485	1,640,508	1,459,239
Selling, general and administrative	328,984	306,501	1,277,852	990,123
Amortization of intangible assets	188	187	751	750
Total expenses	848,717	785,718	3,205,586	2,615,018
Loss from operations	(468,622)	(571,739)	(1,789,665)	(1,438,735)
Interest (expense) income, net	18,219	(4,482)	52,480	(15,757)
Other (expense) income, net	19,438	(10,583)	(223,852)	15,904
Loss before income taxes	(430,965)	(586,804)	(1,961,037)	(1,438,588)
Income tax expense (benefit)	14,370	3,874	42,778	19,228
Net loss	(445,335)	(590,678)	(2,003,815)	(1,457,816)
Less: Net income (loss) attributable to noncontrolling interest	—	—	—	—
Net loss attributable to BeiGene, Ltd.	$ (445,335)	$ (590,678)	$ (2,003,815)	$ (1,457,816)
Net loss per share attributable to BeiGene, Ltd., basic and diluted	$ (0.33)	$ (0.48)	$ (1.49)	$ (1.21)
Weighted-average shares outstanding, basic and diluted	1,348,916,108	1,235,346,414	1,340,729,572	1,206,210,049
Net loss per ADS attributable to BeiGene, Ltd., basic and diluted	$ (4.29)	$ (6.22)	$ (19.43)	$ (15.71)
Weighted-average ADSs outstanding, basic and diluted	103,762,778	95,026,647	103,133,044	92,785,388

We revised certain prior period financial statements for an error related to the valuation of net deferred tax assets, the impact of which was immaterial to our previously filed financial statements in the first and second quarters of 2022 and the quarterly and annual periods of fiscal 2021 (see "Notes to the Condensed Consolidated Financial Statements, Note 1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies" and "Note 2. Revision of Prior Period Financial Statements" included in our Quarterly Report on Form 10-Q for the period ended September 30, 2022 filed with the SEC).